Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $8 to $7.
Stocks · News reference
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 25 percent decrease over losses of $(0.32) per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Annovis Bio, Inc. (ANVS)
Filed: 2026-08-14 AccNo: 0001104659-26-097091 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028